recent articles

Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the...

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – and Visiopharm today announced a collaboration to pair the company’s Hyperion™ and Hyperion+™ Imaging...

Deep Bio said it signed a partnership with Visiopharm, a Danish pharmaceutical company, to supply DeepDx Prostate, its deep learning-based prostate cancer pathology image analysis software. Under the agreement, Deep Bio will be able to...

Proscia invites you to join them for a live virtual panel discussion. Title: Panel Discussion: The Use of AI in Routine, High-Throughput Workflows Date: Tuesday, August 30, 2022 Time: 11:00 AM Eastern Daylight Time Duration: 1...

Visiopharm: Join us on 5 September in Basel, Switzerland for our breakfast symposium at the 2022 European Congress of Pathology (ECP). Learn more about how existing manual processes in the histopathology lab can be optimized to introduce...

Visiopharm are pleased to announce the novel launch of an automated, and IVDR certified, AI-driven digital pathology workflow for University Medical Center Utrecht (UMCU) in the Netherlands. The workflow will be based on existing and new next...

OR

platinum partners

gold partners

Silver Partners

Media Partners